TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24036846
Drug: Nilotinib 400
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 400 mg p.o.
Study: 24036846
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 4,000 mg (4 X Tums Ultra 1000®) p.o. 15 min prior to nilotinib dose.
Study: 15342446
Drug: Current hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current hormone replacement therapy (HRT) users
Study: 8314169
Drug: sustained-release bezafibrate
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained-release bezafibrate 400 mg (n = 21)
Study: 25348661
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon (Peg-IFN) add-on therapy
Study: 25574800
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at an effect-site concentration of 2.5 µg/mL combined with remifentanil (0.25 to 0.35 μg/kg/min) and cisatracurium (0.03 to 0.04 mg/kg/h)
Study: 31937137
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical therapy + structured exercise therapy (nonrevascularization group)
Study: 16840657
Drug: albumin infusion
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: albumin infusion (control)
Study: 23430192
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (GLA) at bedtime
Study: 23430192
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) 1,000 mg b.i.d.
Study: 9828987
Drug: Graded exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded exercise and placebo drug
Study: 2901668
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin G (400 mg per kilogram of body weight) every three weeks for one year
Study: 24448652
Drug: Omeprazole/sodium bicarbonate
Normalized name: OMEPRAZOLE/SODIUM BICARBONATE
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole/sodium bicarbonate (Zegerid(®)) 40 mg once daily for 8 weeks (morning dosing)
Study: 11477842
Drug: Salvia Miltiorrhizae
Normalized name: Salvia miltiorrhiza root extract
DrugBank: Salvia miltiorrhiza root (DB14337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia Miltiorrhizae Composita (SMC) administered intravenously (16 ml) before NTG utilization
Study: 8232870
Drug: Gadodiamide injection
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadodiamide injection (Omniscan)
Study: 29978932
Drug: Delayed VT
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed VT therapy (Arm C)
Study: 9182114
Drug: Doxycycline 300
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 300 mg as a single dose on admission
Study: 28658329
Drug: Non-adherent Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non-adherent Ibuprofen foam dressing (IFD)
Study: 24619855
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (F)
Study: 20627032
Drug: Ilaprazole 5
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 5 mg/d
Study: 29320597
Drug: SPF 70
Normalized name: Coppertone Kids Sunscreen SPF 70
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPF 70 sunscreen applied at 2 mg/cm2
Study: 14728888
Drug: Methylprednisolone pulse
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulse therapy (MPT) intravenously (30 mg/kg) for 3 days followed by oral prednisone
Study: 10411811
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (chosen by women in phase 2)
Study: 8873488
Drug: Multidisciplinary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidisciplinary intervention (comprehensive patient education, dietary and social service consultations, medication review, intensive postdischarge follow‐up)
Study: 804914
Drug: Cromoglycic acid
Normalized name: Cromoglycic acid
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromoglycic acid tablets
Study: 29987587
Drug: Bilateral botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral botulinum toxin (BT) therapy using CBTX‐A, standard doses on affected side, one-third doses on non-affected side
Study: 31468402
Drug: Dietary taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dietary taurine supplementation (3 g of taurine)
Study: 24608161
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (Goserelin)
Study: 24608161
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist + GnRH antagonist (Goserelin and Cetrorelix)
Study: 8147338
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (60 or 120 mg Fe/d)
Study: 30066465
Drug: Dexamethasone group
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone group (20 mL bupivacaine 0.5% + 2 mL dexamethasone 8 mg)
Study: 30213173
Drug: Preoperative parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Preoperative parecoxib administration (40 mg before skin incision and at 12 and 24 hours after the first dose)
Study: 21455724
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate salt (10 mg, twice daily until day seven of age)
Study: 11955846
Drug: Gamma intracoronary
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma intracoronary radiation therapy (ICRT)
Study: 15497666
Drug: Clarithromycin suspension
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin suspension 250 mg/5 mL (Klaromin)
Study: 18388088
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/d and indapamide 2.5 mg/d, increasing amlodipine to 10 mg/d
Study: 19105585
Drug: Cilomilast 15
Normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilomilast 15 mg, twice daily for 24 weeks
Study: 9316524
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (TD‐NTG) 0.2 to 0.4 mg/h
Study: 8566980
Drug: Podophyllotoxin cream
Normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Podophyllotoxin cream 0.5%
Study: 19767384
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin pump therapy (CSII group) with protocol compliance
Study: 22430976
Drug: Single administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration of 100 mg of ferroquine
Study: 12208409
Drug: Omapatrilat 40
Normalized name: OMAPATRILAT
DrugBank: Omapatrilat (DB00886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat 40 mg/day
Study: 8269450
Drug: Dinoprostone cervical
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone cervical gel 0.5 mg administered 12 hours prior to oxytocin induction
Study: 9134079
Drug: Randomly assigned
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomly assigned to intensive group therapy
Study: 21672211
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise therapy (AET) + usual care
Study: 23152592
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of oxytocin (OXT)
Study: 29023327
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) supplementation (0.2 g·kg)
Study: 23587162
Drug: Peretinoin 300
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peretinoin 300 mg daily
Study: 8829017
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (30 mg QD, titrated to 60 mg QD after 4 weeks, then to 90 mg QD after 8 weeks)
Study: 8131528
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (4 g IV over 30 min)
Study: 15252267
Drug: Modafinil 600-mg
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 600-mg split dose (400 mg at 7 AM; 200 mg at noon)
Study: 29653037
Drug: Target-Controlled Infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-Controlled Infusion (TCI)
Study: 8227900
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion at high-dose (2.0 micrograms/min)
Study: 36048
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (LRS)
Study: 22155755
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg at weeks 0, 2, and 6
Study: 9418187
Drug: Killed streptococcal
Normalized name: Streptococcal fibrinolysin
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed streptococcal preparation (KSP), low doses administered before and during early pregnancy.
Study: 16640101
Drug: pegylated interferon-alpha2a
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon-alpha2a 180 mg weekly plus placebo (24 patients)
Study: 23421600
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC)
Study: 19245692
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention for patients (6-month intervention with 20 group sessions and 12 monthly phone contacts)
Study: 18777489
Drug: Muraglitazar 5
Normalized name: Muraglitazar
DrugBank: Muraglitazar (DB06510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muraglitazar 5 mg plus metformin
Study: 30476517
Drug: Ranibizumab or
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab or Bevacizumab (anti-VEGF treatment)
Study: 24085378
Drug: Home exercise
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home exercise therapy
Study: 22688337
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (0.1 and 0.2 units/kg)
Study: 26272281
Drug: S0597 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S0597 at 800 μg/d
Study: 31953790
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimethyl fumarate (DMF) 240 mg
Study: 29901860
Drug: BGF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF MDI 320/14.4/10 μg
Study: 20837852
Drug: Immune globulin
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune globulin intravenous, 10% caprylate‐chromatography purified (2 g/kg loading dose, 1 g/kg maintenance every 3 weeks)
Study: 7082538
Drug: Long-term oral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oral cimetidine treatment
Study: 3378514
Drug: Atenolol 50mg
Normalized name: ATENOLOL 50MG TAB
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 50mg twice daily with sustained release nifedipine 20mg twice daily
Study: 20958119
Drug: Ciclesonide 320
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 320 μg b.i.d.
Study: 20958119
Drug: Ciclesonide 640
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 640 μg b.i.d.
Study: 2242408
Drug: Progabide as
Normalized name: progabide
DrugBank: Progabide (DB00837)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progabide as an adjuvant therapy for partial seizures
Study: 19542238
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (Nebido)
Study: 18173766
Drug: Intralesional clostridial
Normalized name: Clostridium tetani
DrugBank: Clostridium tetani (DB09876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional clostridial collagenase injection therapy (10,000 units, 0.25 cm³ per injection, administered over 7-10 days, with a repeat treatment at 3 months)
Study: 21111980
Drug: Low-dose furosemide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose furosemide combined with low-dose dopamine (LDFD)
Study: 14753248
Drug: Budesonide CFC
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide CFC 400 microg twice daily
Study: 17581288
Drug: Botulinum toxin-A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin-A (BTX-A) injections
Study: 3288845
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate (E2V) (2 mg)
Study: 10784225
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro
Study: 9607830
Drug: nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nelfinavir mesylate (open-label extension with nucleoside inhibitors of reverse transcriptase)
Study: 8590519
Drug: 3-week intensive
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week intensive treatment program (n = 55)
Study: 9243561
Drug: Hair testing
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hair testing for drugs of abuse (cocaine and opiates)
Study: 11963733
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (100 micrograms)
Study: 21328517
Drug: Balaglitazone 20
Normalized name: Balaglitazone
DrugBank: Balaglitazone (DB12781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balaglitazone 20 mg
Study: 16612068
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) for 4 weeks
Study: 8795441
Drug: Simultaneous infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous infusion of gludopa and gamma‐L‐glutamyl‐5‐hydroxy‐L‐tryptophan
Study: 11986264
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) treatment for non-consecutive periods of 2 months and 1 month
Study: 18684311
Drug: Low-dose KRG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose KRG (4.5 g/day)
Study: 29120040
Drug: Prostin 15M
Normalized name: Prostin VR
DrugBank: Carboprost tromethamine (DB00429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostin 15M (15(S)15 methyl PGF2alpha) at a dose of 250 microg
Study: 1877512
Drug: Weekly doses
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly doses of 8.7 mumol (2500 microgram) vitamin A and 46 mumol (20 mg) vitamin E
Study: 8992678
Drug: Oral Sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Sumatriptan (100 mg)
Study: 12774013
Drug: 10 mIU
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mIU IFN‐alpha2b daily for 1 month followed by 3 mIU IFN‐alpha2b 3 times a week with ribavirin
Study: 18374840
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (once daily)
Study: 27329542
Drug: Testosterone solution
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone solution 2%
Study: 24491642
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment after prior laser
Study: 7276229
Drug: 20-30 mg
Normalized name: vilazodone
DrugBank: Vilazodone (DB06684)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-30 mg tranylcypromine
Study: 11379842
Drug: Olanzapine monotherapy
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine monotherapy
Study: 23052105
Drug: Problem-Solving Treatment
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-Solving Treatment (PST) delivered by mental health nurses
Study: 23052105
Drug: Problem-Solving Treatment
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-Solving Treatment (PST)
Study: 22658895
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (glargine plus aspart)
Study: 20500134
Drug: Antibiotics (amoxicillin)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics (amoxicillin) for a 10-day course
Study: 7945002
Drug: Gabapentin therapy
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin therapy
Study: 26653612
Drug: Gliclazide MR
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide MR 60 mg once daily (ADD group)
Study: 31198939
Drug: XAP +
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: XAP + probiotics (2,000 U xylanase + 200 U amylase + 4,000 U protease/kg diet + 75,000 CFU/g of Bacillus spp.)
Study: 12597676
Drug: Patented chamomile
Normalized name: Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patented chamomile preparation
Study: 28710224
Drug: Sensor-augmented insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensor-augmented insulin pump therapy
Study: 12787260
Drug: Oral nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nefopam (20 mg)
Study: 29986700
Drug: Traditional dosing
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dosing
Study: 19690618
Drug: artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: artemether-lumefantrine (AL) six doses over three days (N = 458)
Study: 21788837
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light treatment (two times per week for 4 weeks using a Harmony Laser)
Study: 21502557
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with cisplatin, methotrexate, and vinblastine (CMV), 3 cycles.
Study: 9745100
Drug: Intravenous prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prostaglandin E2
Study: 19766534
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir for 6 weeks
Study: 26256300
Drug: Propofol supplementation
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol supplementation in cardioplegia (6 μg/mL)